Credit squeeze begins to have an impact on VC

The Star-Ledger offers a new perspective on the investment scene in biotechnology. Analysts tell the newspaper that the credit crunch has put a squeeze on private equity groups who can no longer use cheap debt to buy into developers and then flip them. As a result, VCs are accepting smaller returns on smaller deals. With Big Pharma on the hunt for acquisitions, venture groups are less likely to relinquish shares before a big buyout. And buyouts have replaced IPOs as a key funding stage for biotechs.

- read the report from the Star-Ledger

Related Articles:
Will private equity get a crush on biotechnology? Report
Biotech, emerging markets are big VC targets. Report
VC adds billions in its pursuit of biotech ventures. Report
Biotech sees big money from corporate players. Report
Top 20 VC deals of 2007. Report